Synopsis
Synopsis
0
USDMF
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hyperlipen
2. Lipanor
3. Modalim
4. Oroxadin
5. Win 35,833
1. 52214-84-3
2. 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic Acid
3. Lipanor
4. Ciprofibratum
5. 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic Acid
6. Ciprofibrato
7. Modalim
8. Win 35833
9. Win-35833
10. Propanoic Acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-
11. Mfcd00467135
12. 2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic Acid
13. Nsc-759617
14. F8252jgo9s
15. Chebi:50867
16. Propanoic Acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-
17. Ncgc00164447-01
18. 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic Acid
19. Dsstox_cid_331
20. Dsstox_rid_75519
21. Dsstox_gsid_20331
22. Ciprofibratum [inn-latin]
23. Ciprofibrato [inn-spanish]
24. Hiperlipen
25. Ciprol
26. Smr000857190
27. Ccris 173
28. Sr-01000075734
29. Einecs 257-744-6
30. Ciprofibrate (usan/inn)
31. Brn 1984981
32. Unii-f8252jgo9s
33. 2-[p-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid
34. Ciprofibrate?
35. Ciprofibrate [usan:inn:ban]
36. 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic Acid
37. 2-[p-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic Acid
38. Cas-52214-84-3
39. Ciprofibrate- Bio-x
40. Prestwick0_001076
41. Prestwick1_001076
42. Prestwick2_001076
43. Prestwick3_001076
44. Ciprofibrate [mi]
45. Ciprofibrate [inn]
46. C 0330
47. Ciprofibrate [usan]
48. Lopac0_000168
49. Schembl26870
50. Bspbio_001092
51. Ciprofibrate [mart.]
52. Mls002154143
53. Mls006011758
54. Ciprofibrate [who-dd]
55. Win35833
56. Spbio_002996
57. Bpbio1_001202
58. Chembl557555
59. Gtpl3438
60. Dtxsid8020331
61. Bcpp000277
62. Ciprofibrate [ep Impurity]
63. Ciprofibrate For System Suitability
64. Hms1571g14
65. Hms2098g14
66. Hms2235j14
67. Hms3260b17
68. Hms3369b22
69. Hms3656p09
70. Hms3715g14
71. Pharmakon1600-01502008
72. Ciprofibrate [ep Monograph]
73. Bcp03728
74. Hy-b0664
75. Tox21_112121
76. Tox21_201359
77. Tox21_302840
78. Tox21_500168
79. Bbl010821
80. Bdbm50371235
81. Nsc759617
82. S2665
83. Stk624758
84. Akos005557843
85. Tox21_112121_1
86. Ac-1018
87. Bcp9000533
88. Ccg-204263
89. Db09064
90. Ks-1201
91. Lp00168
92. Nsc 759617
93. Sdccgsbi-0050156.p002
94. Ncgc00015202-02
95. Ncgc00015202-03
96. Ncgc00015202-04
97. Ncgc00015202-05
98. Ncgc00015202-06
99. Ncgc00015202-08
100. Ncgc00015202-20
101. Ncgc00015202-21
102. Ncgc00093652-01
103. Ncgc00093652-02
104. Ncgc00256361-01
105. Ncgc00258911-01
106. Ncgc00260853-01
107. Bd164311
108. Bcp0726000148
109. Ab00514032
110. Eu-0100168
111. Ft-0602946
112. Sw197242-4
113. D03521
114. O10468
115. Ab00514032_06
116. 214c843
117. A828985
118. J-520054
119. Q3496452
120. Sr-01000075734-1
121. Sr-01000075734-4
122. Sr-01000075734-7
123. Brd-a49358627-001-03-9
124. Brd-a49358627-001-10-4
125. 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid
126. Ciprofibrate, European Pharmacopoeia (ep) Reference Standard
127. 2-[4-[2,2-bis(chloranyl)cyclopropyl]phenoxy]-2-methyl-propanoic Acid
128. Ciprofibrate For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 289.15 g/mol |
---|---|
Molecular Formula | C13H14Cl2O3 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 288.0319997 g/mol |
Monoisotopic Mass | 288.0319997 g/mol |
Topological Polar Surface Area | 46.5 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 333 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Peroxisome Proliferators
A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration. (See all compounds classified as Peroxisome Proliferators.)
Hypolipidemic Agents
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)
C10AB08
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C10 - Lipid modifying agents
C10A - Lipid modifying agents, plain
C10AB - Fibrates
C10AB08 - Ciprofibrate
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
About the Company : Nhwa is specialized in manufacturing APIs and dosages in the field of Central Nervous System. With 40 years of experience and excellent reputation, Nhwa has become the leader of ma...
About the Company : Dorrapharma is engaged in R&D, manufacture and market of intermediate, API (Active Pharmaceutical Ingredients) and formulation. We stick to raise the value both for the company and...
About the Company : We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Ecuador
Brand Name : Acrofibrato
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ecuador
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Ecuador
Brand Name : Acrofibrato
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ecuador
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 100MG
Brand Name : Acrofibrato
Approval Date :
Application Number :
Registration Country : Ecuador
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 100MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
https://www.pharmacompass.com/radio-compass-blog/niche-european-molecules-is-there-a-business-opportunity-worth-pursuing
Market Place
Reply
11 Sep 2023
Reply
19 Nov 2022
Reply
02 Feb 2022
Reply
28 Mar 2020
Reply
27 Dec 2021
Reply
04 Jul 2016
REF. STANDARDS & IMPURITIES
Ciprofibrate
CAS Number : 52214-84-3
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : Y0000362
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
Ciprofibrate for system suitability
Ciprofibrate for system suitability
CAS Number : 52214-84-3
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : Y0000363
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?